Evidence map›Paper›PMID 39534684›Full record

ArticleFrontiers in cellular neuroscience2024

Region-independent active CNS net uptake of marketed H

Frida Bällgren, Yang Hu, Shannuo Li, Lara van de Beek, Margareta Hammarlund-Udenaes, Irena Loryan

Abstract read
In one paragraph

Article in Frontiers in cellular neuroscience, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Comparative analysis of the uptake of the HFluids and barriers of the CNS · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Frida BällgrenDepartment of Pharmacy, Faculty of Pharmacy, Translational Pharmacokinetics-Pharmacodynamics Group, Translational Pharmacokinetics Pharmacodynamics (tPKPD), Uppsala University, Uppsala, Sweden.
Yang HuDepartment of Pharmacy, Faculty of Pharmacy, Translational Pharmacokinetics-Pharmacodynamics Group, Translational Pharmacokinetics Pharmacodynamics (tPKPD), Uppsala University, Uppsala, Sweden.
Shannuo LiDepartment of Pharmacy, Faculty of Pharmacy, Translational Pharmacokinetics-Pharmacodynamics Group, Translational Pharmacokinetics Pharmacodynamics (tPKPD), Uppsala University, Uppsala, Sweden.
Lara van de BeekDepartment of Pharmacy, Faculty of Pharmacy, Translational Pharmacokinetics-Pharmacodynamics Group, Translational Pharmacokinetics Pharmacodynamics (tPKPD), Uppsala University, Uppsala, Sweden.
Margareta Hammarlund-UdenaesDepartment of Pharmacy, Faculty of Pharmacy, Translational Pharmacokinetics-Pharmacodynamics Group, Translational Pharmacokinetics Pharmacodynamics (tPKPD), Uppsala University, Uppsala, Sweden.
Irena LoryanDepartment of Pharmacy, Faculty of Pharmacy, Translational Pharmacokinetics-Pharmacodynamics Group, Translational Pharmacokinetics Pharmacodynamics (tPKPD), Uppsala University, Uppsala, Sweden.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The pyrilamine-sensitive proton-coupled organic cation (H

Indexed as

active uptakeblood-brain barrierblood-CSF barrierblood-spinal cord barrierKp,uuneurotoxicitypH modulationpyrilamine-sensitive proton-coupled organic cation (H+/OC) antiporter

Identifiers

PMID39534684
PMCPMC11554538

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.